While the risk of delayed radiation nephropathy from RLT is unlikely to impact clinical decision-making for patients with very end stage mCRPC and limited life expectancy, the potential also exists for use of 177Lu-labelled PSMA RLT earlier in prostate cancer care (see ongoing trials such as NCT04720157 and NCT06066437). This evidence concerns the gene FOLH1 and prostate carcinoma.